重症监护病房产AmpC酶阴沟肠杆菌检测及耐药性分析  

Clinical Distribution Characteristics and Drug-resistance of AmpC-producing Enterobacter cloacae in ICU

作　　者：陈红梅[1] 唐芹芳[1] 朱晖[1] 居会祥[1] 孙明忠[1] 

机构地区：[1]东南大学医学院附属盐城医院检验科,江苏盐城224001

出　　处：《中华医院感染学杂志》2009年第18期2495-2496,共2页Chinese Journal of Nosocomiology

摘　　要：目的探讨重症监护病房(ICU)阴沟肠杆菌产AmpC酶所致医院感染的临床特点及细菌的耐药情况。方法收集2005年1月-2006年1月ICU临床分离的阴沟肠杆菌78株,对其进行AmpC酶检测并采用K-B法对临床常用抗菌药物进行体外药敏试验。结果78株阴沟肠杆菌中共检测到AmpC酶阳性菌株32株,阳性率为41.0%;感染部位主要分布于下呼吸道和外科手术部位;药敏结果显示上述产AmpC酶革兰阴性杆菌均对亚胺培南(96.9%)和美罗培南(93.8%)高度敏感。结论产AmpC酶阴沟肠杆菌已成为ICU医院感染的主要致病菌之一,亚胺培南和美罗培南对其仍有显著的抗菌活性,为产AmpC酶阴沟肠杆菌感染的治疗首选药物。OBJECTIVE To explore the clinical distribution characteristics and the drug-resistance of AmpC- producing Enterobacter cloacae in ICU. METHODS Seventy-eight strains of E. cloacae were isolated in ICU from Jan 2005 to Jan 2006 and antimicrocal sensitivities were determined by K-B method. RESULTS Among 78 E. cloa- cal strains derived from the lower respiratory tract and wound secretion, 32 （41.0%） were AmpC producing and were sensitive to imipenem （96.9 %） and merapenem （93.8%）. CONCLUSIONS AmpC-producing E. cloacae is one of the main pathgens of nosocomial infection in ICU,imipenem and merapenem are the first choice to treat the infection.

关 键 词：重症监护病房 阴沟肠杆菌 AMPC酶 耐药性 

分 类 号：R378[医药卫生—病原生物学]